Among NSCLC patients who may undergo resection and qualify for adjuvant therapy, 70,602 patients are anticipated to be epidermal growth factor receptor–negative and treated with adjuvant atezolizumab or pembrolizumab. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.